LSE:OXB

Oxford Biomedica plc · LSE · Healthcare · GBP · FY for 2025

Figures on this page computed 2026-11-07 13:01 UTC

Last close

n/aGBp

Market data

We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-07
Reported in
GBp
- computed
- Computed from the filing for 2025
-19.9%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-17.9%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
-6.0%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
1.62Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
GBp
- computed

Safety is the furthest below its sector's middle: 0.35 against 0.58 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.77x

1.03x

0.61x

2.36x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.77x
Its own average over 10 years, 95.4M.
Profit1.03x
Its own average over 10 years, -29.1M.
Free cash flow0.61x
Its own average over 10 years, -16.7M.
Debt2.36x
Its own average over 10 years, 62.7M.
Pricen/a
Its own average over 0 years. Market data

Debt is furthest from its own average, at 2.36 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	100.0
2017-12-31	135.3	111.4
2018-12-31	240.4	124.6
2019-12-31	230.6	130.9
2020-12-31	315.8	143.9
2021-12-31	514.1	154.1
2022-12-31	504.0	170.7
2023-12-31	322.4	173.8
2024-12-31	463.7	186.2
2025-12-31	607.5	201.4

How sales was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: GBP

How shares in issue was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: GBP

Figures behind the shape

Growth

14.0%

faster is higher, placed against 4,950 companies as of 2026-11-06

Five-year revenue growth rate14.0%
Source
computed
Taken on
2026-11-07
Reported in
GBp
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
GBp
- computed
One-year change in net income30.2%
Source
computed
Taken on
2026-11-07
Reported in
GBp
- computed

Returns on capital

-19.9%

higher is higher, placed against 5,089 companies as of 2026-11-06

Return on invested capital-19.9%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity-33.0%
Net Income / Shareholders' Equity x 100
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets-9.3%
Net Income / Total Assets x 100
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025

Margins

39.1%

wider is higher, placed against 3,412 companies as of 2026-11-06

Gross margin39.1%
Gross Profit / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin-17.6%
Operating Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin-17.9%
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin-6.0%
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025

Price

6.7x

cheaper is higher, placed against 4,362 companies as of 2026-11-06

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-07
Reported in
GBp
- computed
- Computed from the filing for 2025
Price to book6.7x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Taken on
2026-11-07
Reported in
GBp
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
GBp
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio3.6x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Taken on
2026-11-07
Reported in
GBp
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025

Safety

1.62

safer is higher, placed against 3,227 companies as of 2026-11-06

Debt to equity1.62
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio2.20
Current Assets / Current Liabilities
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score0.37
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
GBp
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Taken on
2026-11-07
Reported in
GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
GBp
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.